Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

32.63 +0.55 (+1.73%)
Streaming Delayed Price Updated: 1:40 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
36 37 Next >
Medicago, GSK's Plant-Based COVID-19 Vaccine Candidate Hits 75% Efficacy Against Delta Strain
Canada-based Medicago and GlaxoSmithKline plc (NYSE: GSK) have released Phase 3 data from their plant-derived adjuvanted COVID-19 vaccine candidate.... 
Via Benzinga
Exposures COVID-19
Preclinical Data Shows GSK-Vir COVID-19 Drug Works Against All Omicron Mutations
GlaxoSmithKline plc (NYSE: GSK) said that its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology Inc (NASDAQ: VIR) is effective against all... 
Via Benzinga
Exposures COVID-19
Charms Of China
Today the global stock market rout was pretty awful. 
Via Talk Markets
Why Jim Cramer Likes Enbridge, Vir Biotechnology And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enbridge Inc. (NYSE: 
Via Benzinga
Thursday Markets Overview
Today we are seeing an across-the-board rise in stock prices on hopes for lower inflation and Omicron jabbing. 
Via Talk Markets
AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today
Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). 
Via InvestorPlace
Apple Issues Negative iPhone 13 Forecast as Boeing Gets "Okay" from China
Stock index futures are mixed ahead of the open while investors try to digest yesterday’s selloff. Heavy selling into the close is often seen as a bad sign for stocks, so... 
Via Benzinga
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And Pfizer-... 
Via Benzinga
Exposures COVID-19
VBI Vaccines Reveals Updated Overall Survival Data From Brain Cancer Vaccine Trial
VBI Vaccines Inc (NASDAQ: VBIV) has presented updated 12-month and 18-month overall survival (OS) data from the Phase 2a study of VBI-1901, the Company's... 
Via Benzinga
Britain Agrees To New Deals For 114M Additional Moderna, Pfizer/BioNTech COVID-19 Vaccine Doses
The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (... 
Via Benzinga
Exposures COVID-19
Vir Biotech - GSK's COVID-19 Antibody Shows Preclinical Activity Against Omicron Variant
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced an update to bioRxiv, a preprint server, with preclinical data for... 
Via Benzinga
Exposures COVID-19
Sanofi Adds Acne Vaccine Candidate Via Origimm Biotechnology Acquisition
Sanofi SA (NASDAQ: SNY) has agreed to buy Austrian group Origimm Biotechnology, a move that will add a potential first-in-class vaccine candidate to treat acne... 
Via Benzinga
Why Did HC Wainwright Beef Up Vir Biotech's Target Price?
H.C. Wainwright has raised the Vir Biotechnology Inc (NASDAQ: 
Via Benzinga
Adagio Continues Its Run As Biotech Stocks Moderna, BioNTech Dive On Omicron Threat
Biotech stocks diverged Tuesday with Adagio continuing a run on the potential for its antibody to target Covid's omicron variant. 
Via Investor's Business Daily
Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb
They're very similar companies on the surface, but one is planning for a big disruption. 
Via The Motley Fool
VIR Stock Pops Amid Renewed Omicron Variant Concerns. Here’s Why.
Vir Biotechnology has a Covid-19 treatment that its CEO says will do well against new variants. Amid uncertainty, VIR stock is climbing. 
Via InvestorPlace
Exposures COVID-19
3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a h... 
Via Benzinga
Exposures COVID-19
Should You Buy The Dip In Tilray?
Tilray’s acquisition strategy could drive its long-term growth. However, the company’s shares have fallen in price significantly over the past six months. Furthermore, considering Tilray’s weak bottom... 
Via Talk Markets
1 High-Yield Dividend Stock Worth Buying Right Now
GlaxoSmithKline has been one of the few bright spots in the volatile biopharmaceutical space this year. 
Via The Motley Fool
Exposures COVID-19
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst
Pfizer, Inc. (NYSE:PFE) found huge success with its COVID-19 ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
Exposures COVID-19 Product Safety
GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market... 
Via Benzinga
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
Friday Markets Coverage
Today markets are suffering alongside Austria which locked down against Covid-19 again. 
Via Talk Markets
Exposures COVID-19
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study
CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
Via Benzinga
US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B
The United States government has signed contracts worth about $1 billion to secure the antibody-based COVID-19 treatment developed by GlaxoSmithKline plc (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea... 
Via Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.